IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

doi:10.1038/s43018-026-01199-y

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.

Nature cancer - 1 Aug 2026

Bunse Lukas, Lindner Katharina, Wick Antje, Freitag Angelika, Lanz Lisa-Marie, Edelmann Dominic, Suwala Abigail, Breckwoldt Michael O, Harting Inga, Sahm Felix, Schlenk Richard F, Schmitt Anita, Schnell Oliver, Hense Jörg, Misch Martin, Krex Dietmar, Denk Monika, Walz Juliane, Steinbach Joachim P, von Deimling Andreas, Schmitt Michael, Bunse Theresa, Tabatabai Ghazaleh, Bendszus Martin, Poschke Isabel, Wick Wolfgang, Platten Michael

Abstract excerpt

The clonal glioma driver mutation IDH1R132H gives rise to a major histocompatibility class II-restricted neoepitope. A multicenter, first-in-human phase 1 trial met its prespecified primary endpoints by demonstrating safety and immunogenicity of an IDH1-R132H peptide vaccine (IDH1-vac) integrated into standard of care in 33 participants with newly diagnosed grade III and IV (World Health Organization...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Astrocytoma

Share to Brain Neoplasms

Share to Cancer Vaccines

Share to IDH1 gene

Share to Isocitrate Dehydrogenase

Share to Mutation

Share to Vaccines, Subunit

Source

Open in PubMed Open full text

Identifiers

PMID: 42387024
DOI: 10.1038/s43018-026-01199-y
PMCID: PMC13498463

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1-mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial.PMID 42387024Read ↗

A vaccine targeting mutant IDH1 in newly diagnosed glioma.Semantic proximity Read ↗

In-depth characterization of vaccine-induced neoantigen-specific T cells in patients with IDH1-mutant glioma undergoing personalized peptide vaccination.Semantic proximity Read ↗

A vaccine targeting mutant IDH1 induces antitumour immunity.Semantic proximity Read ↗

Vaccination for IDH-mutant tumors: A novel therapeutic approach applied to glioma.Semantic proximity Read ↗

IDH mutation, glioma immunogenicity, and therapeutic challenge of primary mismatch repair deficient IDH-mutant astrocytoma PMMRDIA: a systematic review.Semantic proximity Read ↗

A Specific Peptide Vaccine Against IDH1(R132H) Glioma.Semantic proximity Read ↗

The first-in-human phase I study of a brain-penetrant mutant IDH1 inhibitor DS-1001 in patients with recurrent or progressive IDH1-mutant gliomas.Semantic proximity Read ↗

Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.Semantic proximity Read ↗

INTERCEPT H3: a multicenter phase I peptide vaccine trial for the treatment of H3-mutated diffuse midline gliomasSemantic proximity Read ↗

A first-in-human peptide vaccine targeting H3K27M; encouraging early findings in 8 adults with diffuse midline glioma.Semantic proximity Read ↗

Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies.Semantic proximity Read ↗

A H3K27M-targeted vaccine in adults with diffuse midline glioma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.